Estazolam is an intermediate-acting benzodiazepine drug that has anxiolytic, hypnotic, anticonvulsant, and muscle-relaxing properties. It is commonly used in patients with problems related to sleep such as difficulty falling asleep and frequent nocturnal awakenings.
Estazolam Uses:
-
Insomnia:
- It is indicated for the management of patients who have difficulty falling asleep, or have frequent awakenings while asleep and early morning awakening.
Read:
Estazolam Dose in Adults
Estazolam Dose in the treatment of Insomnia:
- 1 mg orally at bedtime.
- A dose of 2 mg may be required by some patients.
Dose in Children:
Not indicated.
Pregnancy Risk Factor X
- All benzodiazepines are capable of crossing the placental barrier. They have been linked to teratogenic effects.
- Pregnancy with benzodiazepines can lead to an increase in premature births and low birth weight.
- If taken during the third trimester and before delivery, there may be hypoglycemia or respiratory problems in the neonate.
- Within days or weeks of birth, neonates can experience withdrawal symptoms known as "floppy infant syndrome".
- It is not advised to use estazolam when pregnant.
Use while breastfeeding
- It is unknown if the drug will be excreted into breastmilk. However, benzodiazepines may cross the placental boundary.
- Breastfeeding infants can experience drowsiness, lethargy and weight loss after the mother uses benzodiazepines.
- Manufacturer recommends that you avoid breastfeeding.
Dose in Kidney Disease:
It has not been studied in patients with kidney disease. The manufacturer has not recommended any adjustment in the dose, however, it should be used with caution.
Dose in Liver disease:
It has not been studied in patients with kidney disease. The manufacturer has not recommended any adjustment in the dose, however, it should be used with caution.
Common Side Effects of Estazolam:
-
Central nervous system:
- Drowsiness
Less Common Side Effects of Estazolam:
-
Central Nervous System:
- Dizziness
- Ataxia
- Hangover Effect
- Abnormality In Thinking
- Confusion
- Anxiety
-
Dermatologic:
- Pruritus
-
Gastrointestinal:
- Constipation
- Xerostomia
-
Neuromuscular & Skeletal:
- Hypokinesia
- Leg Pain
- Stiffness
Contraindications to Estazolam:
- Itraconazole and ketoconazole concurrently
- Pregnancy
Warnings and precautions
-
Anterograde amnesia
- Patients may experience anterograde amnesia, as with all benzodiazepines.
-
Depression in the CNS:
- Side effects of benzodiazepines include CNS depression and drowsiness.
- Patients who are required to be alert or who use heavy machinery should be aware of the dangers.
-
Hypersensitivity reactions
- It is possible to experience severe allergic reactions, including angioedema or anaphylaxis, after its use. Hypersensitivity reactions can be severe and should not be repeated.
-
Paradoxical reactions
- There have been paradoxical effects associated with benzodiazepines, such as aggression or hyperactivity.
- Paradoxical behavior is more common in patients with personality disorders, older patients, and children with a history with alcohol abuse.
-
Activities that are sleep-related:
- There have been reports of dangerous sleep-related activities associated with the use of benzodiazepines.
- These include sleeping, cooking, making calls and driving.
-
Depression
- Patients with depression have been shown to be at greater risk for suicidal tendencies when taking benzodiazepines.
- It may cause depression symptoms to return.
-
Use of drugs:
- Some patients taking benzodiazepines can develop tolerance and may need to take higher doses.
- Patients can also develop psychological and physical dependence.
- Patients who have a history of substance abuse or severe alcoholism should not use it.
-
Hepatic impairment
- Patients suffering from liver disease or hepatic impairment should be cautious when taking the drug.
-
Renal impairment
- Patients with impaired renal function should be cautious when taking the drug.
-
Respiratory disease
- Patients with chronic lung disease may experience respiratory depression from benzodiazepines.
- These patients should use it with caution.
Estazolam: Drug Interaction
Note: Drug Interaction Categories:
- Risk Factor C: Monitor When Using Combination
- Risk Factor D: Consider Treatment Modification
- Risk Factor X: Avoid Concomitant Use
Risk Factor C (Monitor therapy) |
|
Alcohol (Ethyl) | CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). |
Alizapride | May enhance the CNS depressant effect of CNS Depressants. |
Brexanolone | CNS Depressants may enhance the CNS depressant effect of Brexanolone. |
Brimonidine (Topical) | May enhance the CNS depressant effect of CNS Depressants. |
Bromopride | May enhance the CNS depressant effect of CNS Depressants. |
Cannabidiol | May enhance the CNS depressant effect of CNS Depressants. |
Cannabis | May enhance the CNS depressant effect of CNS Depressants. |
Chlorphenesin Carbamate | May enhance the adverse/toxic effect of CNS Depressants. |
CNS Depressants | May enhance the adverse/toxic effect of other CNS Depressants. |
CYP3A4 Inhibitors (Strong) | May increase the serum concentration of Estazolam. |
Dimethindene (Topical) | May enhance the CNS depressant effect of CNS Depressants. |
Doxylamine | May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. |
Dronabinol | May enhance the CNS depressant effect of CNS Depressants. |
Esketamine | May enhance the CNS depressant effect of CNS Depressants. |
Fosphenytoin | Benzodiazepines may increase the serum concentration of Fosphenytoin. Shortterm exposure to benzodiazepines may not present as much risk as chronic therapy. |
HydrOXYzine | May enhance the CNS depressant effect of CNS Depressants. |
Kava Kava | May enhance the adverse/toxic effect of CNS Depressants. |
Lofexidine | May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. |
Magnesium Sulfate | May enhance the CNS depressant effect of CNS Depressants. |
Melatonin | May enhance the sedative effect of Benzodiazepines. |
MetyroSINE | CNS Depressants may enhance the sedative effect of MetyroSINE. |
Minocycline | May enhance the CNS depressant effect of CNS Depressants. |
Mirtazapine | CNS Depressants may enhance the CNS depressant effect of Mirtazapine. |
Nabilone | May enhance the CNS depressant effect of CNS Depressants. |
Phenytoin | Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. |
Piribedil | CNS Depressants may enhance the CNS depressant effect of Piribedil. |
Pramipexole | CNS Depressants may enhance the sedative effect of Pramipexole. |
Ritonavir | May increase the serum concentration of Estazolam. |
ROPINIRole | CNS Depressants may enhance the sedative effect of ROPINIRole. |
Rotigotine | CNS Depressants may enhance the sedative effect of Rotigotine. |
Rufinamide | May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. |
Selective Serotonin Reuptake Inhibitors | CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. |
Teduglutide | May increase the serum concentration of Benzodiazepines. |
Tetrahydrocannabinol | May enhance the CNS depressant effect of CNS Depressants. |
Tetrahydrocannabinol and Cannabidiol | May enhance the CNS depressant effect of CNS Depressants. |
Trimeprazine | May enhance the CNS depressant effect of CNS Depressants. |
Yohimbine | May diminish the therapeutic effect of Antianxiety Agents. |
Risk Factor D (Consider therapy modification) |
|
Blonanserin | CNS Depressants may enhance the CNS depressant effect of Blonanserin. |
Buprenorphine | CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants. |
Chlormethiazole | May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. |
CloZAPine | Benzodiazepines may enhance the adverse/toxic effect of CloZAPine. Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. |
Droperidol | May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs. |
Flunitrazepam | CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. |
HYDROcodone | CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
Macrolide Antibiotics | Estazolam serum concentration can rise. Management: Take into account a less likely to interact option. Azithromycin is most likely a lower-risk macrolide, while benzodiazepines (such as lorazepam and oxazepam) that are less dependent on CYP3A metabolism are also less likely to interact. Azithromycin (Systemic), Fidaxomicin, Roxithromycin, and Spiramycin are exceptions. |
Methadone | Benzodiazepines may enhance the CNS depressant effect of Methadone. Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution. |
Methotrimeprazine | CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. |
Opioid Agonists | CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
OxyCODONE | CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
Perampanel | May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. |
Suvorexant | CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. |
Tapentadol | May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
Zolpidem | CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. |
Risk Factor X (Avoid combination) |
|
Azelastine (Nasal) | CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). |
Bromperidol | May enhance the CNS depressant effect of CNS Depressants. |
Itraconazole | May increase the serum concentration of Estazolam. |
Ketoconazole (Systemic) | May increase the serum concentration of Estazolam. |
OLANZapine | May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration. |
Orphenadrine | CNS Depressants may enhance the CNS depressant effect of Orphenadrine. |
Oxomemazine | May enhance the CNS depressant effect of CNS Depressants. |
Paraldehyde | CNS Depressants may enhance the CNS depressant effect of Paraldehyde. |
Sodium Oxybate | Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate. |
Thalidomide | CNS Depressants may enhance the CNS depressant effect of Thalidomide. |
Theophylline Derivatives | May reduce benzodiazepine's therapeutic impact. |
Monitoring parameters:
- Particularly in individuals with underlying organ failure, keep an eye on the patient's respiratory and cardiovascular health.
- CBC and urinalysis periodically
- Observe for daytime somnolence;
- Assess behavior profile
How to administer Estazolam?
- Administer the drug orally at bedtime preferably without a meal (on an empty stomach).
- It should be taken just prior to getting into bed or when in bed.
Mechanism of action of Estazolam:
- By interacting with the postsynaptic GABA Neuron's typical benzodiazepine receptors at various locations across the central nervous systems, it strengthens the inhibitory impact of GABA.
- These receptors are found mainly in the limbic and reticular activating systems.
- By increasing the permeability of neurons' membranes to chloride ions and resulting hyperpolarization, it amplifies the effects of GABA.
Duration of the effect:
- Variable The excitability of neurons decreases in hyperpolarized conditions.
- GABA A receptors are a binding site for benzos. They are not able to bind to GABA B receptors.
Protein binding:
- 93%
Metabolism:
- It is metabolized extensively in the liver to 11 inactive metabolites including 1-oxo-estazolam and 4-hydroxy-estazolam.
- Its metabolism to 4-hydroxy-estazolam is mediated by CYP3A4
Half-life elimination:
- 10 to 24 hours
Time to peak, serum:
- About two 2 hours (range: 0.5 to 6 hours)
Excretion:
- Urine (Less than 5% of the drug is excreted as unchanged drug and more than 70% is excreted as inactive metabolites);
- feces (4%)
International Brands of Estazolam:
- Domnamid
- Esilgan
- Eslam
- Estalin
- Estazolam
- Eszo 2
- Eurodin
- Kainever
- Kinzolam
- Noctal
- Nuctalon
- Sedarest
- Somnatrol
- Tasedan
Estazolam Brand Names in Pakistan:
Estazolam Tablets 1 mg in Pakistan |
|
Esilgan | Helix Pharma (Private) Limited |
Estazolam Tablets 2 mg in Pakistan |
|
Esilgan | Helix Pharma (Private) Limited |